RT Journal Article
SR Electronic
T1 Excess Mortality probably due to COVID-19 in Tokyo, Japan between August and October, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.09.20143164
DO 10.1101/2020.07.09.20143164
A1 Kurita, Junko
A1 Sugawara, Tamie
A1 Sugishita, Yoshiyuki
A1 Ohkusa, Yasushi
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2020.07.09.20143164.abstract
AB Background As of March, 2021, the COVID-19 outbreak has been record the highest peak in the end of December, 2020. Nevertheless, no remarkable excess mortality attributable to COVID-19 has been observed.Object We sought to quantify excess mortality in April using the National Institute of Infectious Diseases (NIID) model.Method We applied the NIID model to deaths of all causes from 1987 up through January, 2021 for the whole of Japan and up through October for Tokyo.Results Results in Japan show very few excess mortality in August and October, 2020 It was estimated as 12 and 104. Conversely, in Tokyo, 595 excess mortality was detected between August and Octoember, which was 3.1% and 1.7% of baseline.Discussion and Conclusion We detected substantial excess mortality in Tokyo but a few in Japan. It might be important to continue to monitor excess mortality of COVID-19 carefully hereafter.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMinistry of Health, Labour and Welfare. Preliminary statistics on demographics https://www.mhlw.go.jp/toukei/list/81-1a.html